In its statement, GSK said the $30 billion investment would include capital investments in its U.S. supply chain and more ...

British Big Pharma GSK is welcoming President Donald Trump to the U.K. with a hefty gift: a five-year, $30 billion planned ...

British pharmaceutical firm GSK has pledged to invest $30bn (£22bn) in research and manufacturing in the US over the next ...

The pharmaceutical company plans to break ground on a new manufacturing facility in Upper Merion, Pennsylvania, in 2026.

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug ...

The FDA reapproved a GSK drug that stopped being sold more than 25 years ago, as part of a push to identify potential ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...

GlaxoSmithKline has announced a $30 billion investment across US R&D and manufacturing over the next five years. Projects ...

GSK ( NYSE: GSK) said it is planning to invest at least $30B across the U.S. in research and development and supply chain ...

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there ...

GSK is leaning hard into its U.S. footprint with a $30 billion commitment over the next five yearsan investment wave that ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...